|
Wall Street Grand Report
Company: Echo Therapeutics, Inc. (OTCBB: ECTE)
Current PPS: $2.02
In the next 3 years, ECTE has the potential of changing the way critical care physicians and nurses, endocrinologists and diabetics view glucose monitoring. In 2003, ECTE completed its first glucose monitoring pilot study using its first generation skin permeation system and glucose flux sensor. Since that time, ECTE has developed a smaller, more advanced skin permeation system, the PreludeTM SkinPrep system. If its clinical trials are positive as its pilot studies, ECTE has an opportunity to become the market leader in the continuous glucose monitoring market!
There are approximately 1.3 million Type I diabetics, and 30 million annual critical care patient days in the United States, alone!
The analyst report mentioned, "While market penetration rates for [Continuous Glucose Monitoring systems] CGMs are in their infancy, we feel these rates could go as high as 20% for both markets due to advancements in CGM technologies and new positive clinical studies."
ECTE is tapping into a multi-billion dollar market that is growing!
Just today, one of ECTE‘s competitors DXCM hit a New 52-week high! ECTE is following in their footsteps and is poised to potential become a major takeover target!
Here are our Top 4 Highlights for ECTE:
#1. ECTE’s trans-dermal system is the ONLY needle-free continuous blood glucose monitoring (CBGM) system in the world. So, ECTE’s Glucose Monitoring System could virtually eliminate the pain that diabetics experience when testing their glucose levels. That means no more needles for this purpose! Don’t forget ECTE has the Patent for this technology!
#2. ECTE Could be a Buyout Candidate. Because other major pharmaceutical companies do not have the technology to monitor glucose levels, and the number of Diabetics worldwide, have grown significantly, ECTE presents itself as a potentially top selection from Diabetic consumers. I’m not the only person that has stated that the Company is positioned nicely as a potential acquisition target. Even the CEO admited that a merger or acquisition was a posibility during an interview that is now available at www.stockgoodies.com.
#3. ECTE Could Potentially Move to a Higher Exchange. According to the Corporate Profile (found at http://brettmaas.com/) one of the "12 Month Milestones" ECTE has is to obtain a listing for the AMEX or Nasdaq. And, in order to achieve that goal the symbol needs to be trading at higher levels…which means the company could be motivated to not dilute their market…which means share prices could SURGE!
#4. ECTE Likely to Obtain Possible FDA Approval. When asked where he thought the company would be 5 years from now, the CEO stated that if not acquired or merged into a larger company – which are distinct possibilities – ECTE would possibly have 3 FDA-approved medical device products on the market. I believe this could be a huge catalyst for a MASSIVELY increased sales stream and help transform it into a major medical device supplier!
Get ready for this week!
More Updates To Come …
Help Spread the word about Wall Street Grand!
You can call us Toll free at 1888-9-Club Grand (1888-925-8247)
Offices are open Monday – Friday, 9:30 am-4:00 pm EST
|
